TTK Healthcare Share Price Target 2026 Analyst Forecast Bull and Bear Case
- June 26, 2026
- Posted by: Kunal Singla
- Category: News
The TTK Healthcare share price target 2026 is Rs 1,100, implying approximately 20 percent upside from the current market price of Rs 933.5 (NSE: TTKHLTCARE). With Q4 FY26 results released in 2026 and Healthcare Products and Consumer Wellness tailwinds in focus, the Rs 1,100 price objective is supported by the FY27 earnings recovery thesis.
TTK Healthcare (NSE: TTKHLTCARE) is a Healthcare Products and Consumer Wellness company trading at Rs 933.5 with a market capitalisation of Rs 1,299 crore. Analysts have set the TTK Healthcare share price target at Rs 1,100 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.
Click Here – Get Free Investment Predictions
TTK Healthcare Share Price Target 2026: Key Takeaways
- TTK Healthcare share price target 2026: Rs 1,100 (20% upside from CMP Rs 933.5)
- Bull case: Rs 1,350 | Bear case: Rs 745
- Ticker: TTKHLTCARE | Sector: Healthcare Products and Consumer Wellness | MCap: Rs 1,299 crore
- 52W range: Rs 735 to Rs 1,399 | PE: 22x
- Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
- Key risk: FY27 earnings miss or FII outflows from Indian equities
TTK Healthcare Company Overview
TTK Healthcare (NSE: TTKHLTCARE) is a Chennai-based TTK Group company manufacturing and marketing contraceptives under Moodseal and Prudence brands, pharmaceutical preparations, and consumer wellness products. At CMP Rs 933.5 against a 52 week range of Rs 735 to Rs 1,399, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 1,299 crore with trailing PE of 22x. Compared to peers in consumer health like Mankind Pharma and Piramal Pharma, TTK Healthcare is positioned as a potential re-rating candidate toward the Rs 1,100 price objective on FY27 earnings delivery.
| Parameter | Value |
|---|---|
| NSE Ticker | TTKHLTCARE |
| Sector | Healthcare Products and Consumer Wellness |
| CMP (2026) | Rs 933.5 |
| 52 Week High | Rs 1,399 |
| 52 Week Low | Rs 735 |
| Market Cap | Rs 1,299 crore |
| Trailing PE | 22x |
| 12-Month Analyst Target | Rs 1,100 |
| Bull Case Target | Rs 1,350 |
| Bear Case Target | Rs 745 |
Why Is the TTK Healthcare Share Price Target Set at Rs 1,100 for 2026
FY27 Earnings Recovery and Revenue Acceleration
The TTK Healthcare share price target of Rs 1,100 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for re-rating from CMP Rs 933.5.
Structural Sector Tailwinds in Healthcare Products and Consumer Wellness
The Healthcare Products and Consumer Wellness sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. TTK Healthcare’s position among peers in consumer health like Mankind Pharma and Piramal Pharma creates a structural growth runway, with sustained outperformance being one of the key conditions for the Rs 1,350 bull case to materialise.
RBI Rate Cut Cycle and Lower Cost of Capital
India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve TTK Healthcare’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 1,100 analyst consensus.
Union Budget 2026-27 Capex Push and Policy Support
Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for TTK Healthcare’s Healthcare Products and Consumer Wellness operations, improving the probability of achieving the Rs 1,100 price objective through FY27 earnings delivery.
FII Flow Normalisation After the 2026 Tariff Shock
As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 22x PE, TTK Healthcare is positioned as a beneficiary of institutional reallocation toward the Rs 1,350 bull case over the medium term.
TTK Healthcare Share Price Targets: Short Term, 12 Month, and Long Term
Short Term TTK Healthcare Share Price Target
Near-term support for TTK Healthcare is anchored close to the 52 week low of Rs 735. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating from CMP Rs 933.5.
12-Month TTK Healthcare Share Price Target 2026
The 12-month TTK Healthcare share price target 2026 is Rs 1,100, implying approximately 20 percent upside from CMP Rs 933.5. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows.
Long Term TTK Healthcare Share Price Target: FY27 to FY28
The long term TTK Healthcare share price target for FY27 to FY28 is Rs 1,350 in the bull case, requiring full earnings delivery, re-rating among peers in consumer health like Mankind Pharma and Piramal Pharma, and sustained institutional buying over a 2 to 3 year horizon.
Bull Case and Bear Case Scenarios for TTK Healthcare in 2026
Bull Case TTK Healthcare Share Price Target: Rs 1,350
The bull case TTK Healthcare share price target of Rs 1,350 materialises when FY27 earnings beat analyst estimates, Healthcare Products and Consumer Wellness tailwinds accelerate, and FII flows return strongly to Indian equities, representing approximately 45 percent potential upside from CMP Rs 933.5.
Bear Case TTK Healthcare Share Price Target: Rs 745
The bear case TTK Healthcare share price target of Rs 745 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 735.
| Scenario | Target | Key Conditions |
|---|---|---|
| Bull Case | Rs 1,350 | FY27 beat, sector re-rating, FII inflows |
| Base Case (Analyst Target) | Rs 1,100 | In-line FY27 delivery, partial FII recovery |
| Bear Case | Rs 745 | FY27 miss, guidance cut, FII outflows persist |
Key Risks That Could Derail the TTK Healthcare 2026 Price Objective
Global Macro and US Tariff Headwinds
Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the TTK Healthcare share price target of Rs 1,100, with FII outflows being the direct transmission mechanism to Indian equity valuations.
FY27 Earnings Miss and Guidance Risk
An FY27 earnings miss or downward guidance revision would compress valuation multiples and is the most direct company-specific risk to the Rs 1,100 analyst price objective. Investors must monitor quarterly results and management commentary closely.
Competitive Intensity Among Healthcare Products and Consumer Wellness Peers
Intensifying competition from peers in consumer health like Mankind Pharma and Piramal Pharma could compress TTK Healthcare’s market share and pricing power, a structural risk that must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 1,100 analyst target for 2026.
Liquidity Risk and FII Selling Pressure
Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.
How to Invest in TTK Healthcare
Check the Univest Screener for live data
Before considering any investment based on the TTK Healthcare share price target of Rs 1,100, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Healthcare Products and Consumer Wellness sector demand.
Open a Demat account with a SEBI registered stockbroker to trade TTK Healthcare (NSE: TTKHLTCARE) with full regulatory protection. Study the competitive landscape among peers in consumer health like Mankind Pharma and Piramal Pharma before executing any position.
Plan your entry using the 52 week low of Rs 735 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 1,100 price objective. Always set a stop loss below the 52 week low.
Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.
Download the Univest iOS App or the Univest Android App to track TTK Healthcare’s live share price and receive daily stock recommendations.
Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.
FAQs on TTK Healthcare Share Price Target 2026
What is the TTK Healthcare share price target for 2026?
Ans. The TTK Healthcare share price target 2026 is Rs 1,100, implying approximately 20 percent upside from CMP Rs 933.5. Bull case is Rs 1,350, bear case is Rs 745.
What was the TTK Healthcare share price target for 2025?
Ans. The 2025 price objective for TTK Healthcare was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 1,100, reflecting FY27 growth potential from CMP Rs 933.5.
Is TTK Healthcare a good investment at Rs 933.5?
Ans. At Rs 933.5, TTK Healthcare offers potential upside toward Rs 1,100 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.
What are the key risks to the TTK Healthcare share price target 2026?
Ans. Key risks to the TTK Healthcare share price target of Rs 1,100 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Healthcare Products and Consumer Wellness. Monitoring quarterly results is essential.
What is the 52 week high and low of TTK Healthcare?
Ans. The 52 week high of TTK Healthcare is Rs 1,399 and the 52 week low is Rs 735. At CMP Rs 933.5, the stock offers potential upside toward the Rs 1,100 price objective.
What are the main growth catalysts for TTK Healthcare in 2026?
Ans. Key catalysts include FY27 PAT recovery, Healthcare Products and Consumer Wellness tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.
How does TTK Healthcare compare to its peers?
Ans. TTK Healthcare operates in Healthcare Products and Consumer Wellness alongside peers in consumer health like Mankind Pharma and Piramal Pharma. At CMP Rs 933.5 with MCap Rs 1,299 crore, it is a potential re-rating candidate toward the TTK Healthcare share price target of Rs 1,100 on FY27 delivery.
What is the TTK Healthcare share price target for 2027?
Ans. The long-term TTK Healthcare share price target for FY27 to FY28 is Rs 1,350 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.
